Study on the pathogenic progression from transient myeloproliferative disorder to acute megakaryoblasticm leukemia in Down syndrome using DNA microarrays

点击翻译按钮获取中文摘要

Approximately 10% of newborns with Down syndrome develop transient myeloproliferative disorder (TMD), a disorder that is unique to infants with constitutional trisomy 21 or trisomy 21 mosaicism. TMD blasts disappear spontaneously within the first 3 months of life in the majority of cases. Despite the resolution of TMD, 20-30% of these newborns will go on to develop acute megakaryoblastic leukemia (AMKL) within the 3 years. In this study, samples from both TMD and AMKL patients were examined using DNA microarrays to study the pathogenic progression from TMD to AMKL. Because we were able to obtain only three high-quality mRNA from each patient group respectively, we could not find different gene expression pattern between two groups. In order to identify genes contributing to develop AMKL from TMD in DS patients using DNA microarrays, we have to increase available number of cases in future. Further studies are needed to identify genes contributing to develop AMKL from TMD in DS patients.